- Home
- OPRT vs AVIR Comparison
OPRT vs AVIR Comparison
Compare OPRT & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRT
- AVIR
- Stock Information
- Founded
- OPRT 2005
- AVIR 2012
- Country
- OPRT United States
- AVIR United States
- Employees
- OPRT N/A
- AVIR N/A
- Industry
- OPRT Finance: Consumer Services
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- OPRT Finance
- AVIR Health Care
- Exchange
- OPRT Nasdaq
- AVIR Nasdaq
- Market Cap
- OPRT 298.8M
- AVIR 273.0M
- IPO Year
- OPRT 2019
- AVIR 2020
- Fundamental
- Price
- OPRT $6.78
- AVIR $3.73
- Analyst Decision
- OPRT Hold
- AVIR Hold
- Analyst Count
- OPRT 2
- AVIR 1
- Target Price
- OPRT $8.00
- AVIR $6.00
- AVG Volume (30 Days)
- OPRT 804.8K
- AVIR 398.9K
- Earning Date
- OPRT 08-07-2025
- AVIR 08-06-2025
- Dividend Yield
- OPRT N/A
- AVIR N/A
- EPS Growth
- OPRT N/A
- AVIR N/A
- EPS
- OPRT N/A
- AVIR N/A
- Revenue
- OPRT $746,101,000.00
- AVIR N/A
- Revenue This Year
- OPRT $28.61
- AVIR N/A
- Revenue Next Year
- OPRT $7.22
- AVIR N/A
- P/E Ratio
- OPRT N/A
- AVIR N/A
- Revenue Growth
- OPRT N/A
- AVIR N/A
- 52 Week Low
- OPRT $2.37
- AVIR $2.46
- 52 Week High
- OPRT $9.25
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- OPRT 48.05
- AVIR 74.60
- Support Level
- OPRT $6.88
- AVIR $3.63
- Resistance Level
- OPRT $7.26
- AVIR $3.78
- Average True Range (ATR)
- OPRT 0.52
- AVIR 0.14
- MACD
- OPRT -0.05
- AVIR 0.02
- Stochastic Oscillator
- OPRT 27.96
- AVIR 100.00
About OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).